Jellagen and Cellaria Inc develop next-generation models for cancer research
New partnership between Jellagen and Cellaria Inc. offers a paradigm shift in collagen chemistry to develop next-generation models for cancer research
View PDFNew partnership between Jellagen and Cellaria Inc. offers a paradigm shift in collagen chemistry to develop next-generation models for cancer research
View PDFJellagen and Copner Biotech ink partnership following SMART Cymru innovation funding award of £123,724
View PDFProfessor Sheila MacNeil is Emeritus Professor of Tissue Engineering at the Department of Materials Science and Engineering, University of Sheffield
View PDFThe partnership agreement enables Jellagen privileged access to Ifremer’s proprietary technology on testing new marine derived natural products for medical research.
View PDFThe first Collagen Type 0 Hydrogel taking on the market leading Extracellular Matrix.
View PDFJellagen Boosts Scientific Advisory Board with New Appointments Dr Mike Barbeck and Dr Andy Weymann
View PDFJellagen signs three new partner and distributor agreements to cover the APAC region
View PDFJellagen has entered into a license agreement for an exclusive grant to patent rights with Mayo Clinic for the development in treatment of vocal cord paralysis.
View PDFMicroglia Cells on Jellagen® demonstrated a more ramified “microglial-like” cell morphology compared to cells cultured on mammalian Rat Tail Collagen I and Laminin-511.
View PDFJellagen® announces £1.9m seed financing to develop products for therapeutic and medical device applications
View PDFGregg replaces Stephane Thiroloix who will remain as a non-executive director at Jellagen®. Gregg founded one of the first cancer immunotherapy biotech companies in 2005 and has pioneered the commercialization of innovative cell therapies for oncology and infectious diseases.
View PDFJellagen jellyfish collagen 3D systems support ovarian cancer cell line proliferation, confirming suitability for advanced cell culturing applications.
View PDFJellagen®, jeune entreprise britannique basée à Cardiff spécialisée en biotechnologie marine lance cette semaine JellaGel ™, le premier Hydrogel de collagène de méduse purifié, conçu pour la culture cellulaire 3D et l’ingénierie tissulaire
View PDFMarine Biotechnologies firm Jellagen announces the appointment of a new CEO
View PDFMarine Biotechnologies firm Jellagen on course for accelerated growth thanks to £3.8m funding from Newable Private Investing, Development Bank of Wales and Angel Investors
View PDF